NexImmune, Inc.
NEXI · OTC
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.01 | 0.00 | -0.00 |
| FCF Yield | -58.19% | -34.63% | -2,302.44% | -132.42% |
| EV / EBITDA | -0.43 | -0.95 | 0.15 | 0.38 |
| Quality | ||||
| ROIC | -312.02% | -63.30% | -101.23% | -112.83% |
| Gross Margin | 0.00% | 0.00% | 89.22% | 0.00% |
| Cash Conversion Ratio | 0.89 | 0.79 | 1.09 | 0.74 |
| Growth | ||||
| Revenue 3-Year CAGR | 1,284,644.36% | 1,284,644.36% | 1,284,644.36% | -100.00% |
| Free Cash Flow Growth | 14.23% | 95.57% | -648.16% | -20.73% |
| Safety | ||||
| Net Debt / EBITDA | 0.91 | 1.69 | 0.61 | 1.10 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | -6.81 |
| Cash Conversion Cycle | -1,529.08 | -604.33 | -526.32 | -263.18 |